Turbare Manufacturing
FDA 503B outsourcing facility
Conway, Arkansas
Key Takeaways
- FDA-registered 503B outsourcing facility since 2023
- Sterile compounding from bulk substances: Yes
- Last FDA inspection: May 7, 2026
- 1 FDA drug recall on record (2025)
About this facility
A 503B outsourcing facility is registered with the FDA under the Drug Quality and Security Act and may compound sterile medications in bulk without patient-specific prescriptions, under cGMP manufacturing standards. How federal compounding status works.
FDA registration and inspection record
- First registered with FDA
- June 23, 2023
- Most recent registration
- December 3, 2025
- Compounds sterile drugs from bulk substances
- Yes
- Last FDA inspection
- May 7, 2026
The FDA last inspected Turbare Manufacturing on May 7, 2026. Investigators issued a Form FDA 483 listing inspectional observations at that visit. The FDA has not yet determined whether further action will be taken.
FDA recall history
Turbare Manufacturing has 1 FDA drug recall on record in 2025, based on the FDA enforcement database. Breakdown: 1 Class II.
Recall reasons on record include lack of assurance of sterility: due to a quality control process deviation.
| Date | Class | Product | Reason |
|---|---|---|---|
| February 2025 | Class II | Avastin 1.25 mg/0.05 mL in 0.25 mL Syringe, For Intravitreal Injection Only, Office Use Only - Not for Resale - Single Use, This drug produc | Lack of Assurance of Sterility: due to a quality control process deviation |
FDA recall classes signal severity, not intent: Class I means a reasonable probability of serious harm, Class II a temporary or reversible risk, Class III a violation unlikely to cause harm. Sterile compounders routinely recall lots as a precaution. FDA definitions.
What this facility compounds
Turbare Manufacturing reports compounding 4 distinct active ingredients to the FDA Outsourcing Facility Product Report (most recent reporting periods).
Tracked on PeptideGrids: Semaglutide.
- Bevacizumab
- Ceftazidime Anhydrous
- Semaglutide
- Vancomycin Hydrochloride
Location
925 Jeanette Dr, N/A, Conway, AR 72032-6651
Satellite and street imagery via Esri. Open larger map.
Contact
FDA-registered contact: Deketric Smith, 501-504-6635. Source: the facility's FDA outsourcing registration.
License verification
503B outsourcing facilities are also licensed by the state board of pharmacy. Verify the current license status of Turbare Manufacturing with the Arkansas State Board of Pharmacy.
503B facilities in Arkansas
Arkansas has 3 FDA-registered 503B outsourcing facilities in the PeptideGrids directory. See all 503B facilities in Arkansas.
Frequently asked questions
Is Turbare Manufacturing registered with the FDA?
Yes. Turbare Manufacturing is a registered 503B outsourcing facility, first registered with the FDA on June 23, 2023 and most recently registered on December 3, 2025.
Has Turbare Manufacturing been inspected by the FDA?
The FDA last inspected Turbare Manufacturing on May 7, 2026. A Form FDA 483 was issued.
Has Turbare Manufacturing had any FDA drug recalls?
Turbare Manufacturing has 1 FDA drug recall on record (2025) in the FDA enforcement database.
What does Turbare Manufacturing compound?
Turbare Manufacturing reports compounding 4 active ingredients to the FDA, including Semaglutide.
Where is Turbare Manufacturing located?
Turbare Manufacturing is located in Conway, Arkansas (925 Jeanette Dr).
Registration and inspection data verified against the FDA list of registered outsourcing facilities on June 6, 2026. Recall history from the FDA openFDA drug enforcement database, retrieved June 6, 2026.
PeptideGrids is independent and not affiliated with, endorsed by, or sponsored by Turbare Manufacturing. Listings, registration, inspection, and recall data are reported from public FDA records for informational purposes only. A recall or inspection finding is not an accusation of current wrongdoing. This is not medical or legal advice. To request a correction, see our corrections policy.